Just how early depends on the patient's CD4-cell count, according to the SAPiT and STRIDE results presented at CROI 2011.
The initial results of the SAPiT trial (JW AIDS Clin Care Feb 24 2010) showed that mortality rates among HIV/tuberculosis (TB)-coinfected patients can be reduced dramatically by initiating antiretroviral therapy (ART) during TB treatment (integrated therapy) rather than afterward (sequential therapy). But when exactly should ART be started during TB treatment? The latest results from the SAPiT and STRIDE trials, presented at CROI 2011, provide further insight into this issue.
In the SAPiT trial, 429 coinfected patients with a median baseline CD4 count of 150 cells/mm3 were randomized to receive either early integrated therapy (ART started within 4 weeks of TB treatment initiation) or late integrated therapy (ART started within the first 4 we…
Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)